James Yates

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Peter Ballard, James Yates, Zhenfan Yang et al. · Clinical Cancer Research · 2016 · 704 citations

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Barry R. Davies, Hannah E. Greenwood, Phillippa Dudley et al. · Molecular Cancer Therapeutics · 2012 · 453 citations

Pharmacotherapy, Cancer Biology, Tumor Biology +18

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

Kevin M. Foote, J. Willem M. Nissink, Thomas M. McGuire et al. · Journal of Medicinal Chemistry · 2018 · 313 citations · Full text

Kinase Ataxia Telangiectasia, Cell Death, Molecular Biology +19

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Nicola Colclough, Kan Chen, Peter Johnström et al. · Clinical Cancer Research · 2020 · 215 citations · Full text

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance

Barbara J. Ring, Jenny Y. Chien, Kimberly K. Adkison et al. · Journal of Pharmaceutical Sciences · 2011 · 198 citations

Pharmacokinetic Modeling, Medicine, Drug Discovery +8